[SC14D9C] LAVA Therapeutics N.V. SEC Filing

Rhea-AI Filing Summary

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14D-9

Solicitation/Recommendation Statement

Under Section 14(d)(4) of the Securities Exchange Act of 1934

(Amendment No. )

LAVA Therapeutics N.V.

(Name of Subject Company)

LAVA Therapeutics N.V.

(Name of Persons Filing Statement)

Common shares, nominal value €0.12 per share

(Title of Class of Securities)

N51517105

(CUSIP Number of Class of Securities)

Stephen Hurly

Chief Executive Officer and President

LAVA Therapeutics N.V.

Yalelaan 62

3584 CM Utrecht, The Netherlands

+31 85 016 3100

(Name, address, and telephone number of person authorized to receive notices and communications

on behalf of the persons filing statement)

With a copy to:

Divakar Gupta

Katie Kazem

Courtney T. Thorne 

Rita Sobral

Cooley LLP

55 Hudson Yards

New York, New York 10001

+1 (212) 479-6000

x Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

This Schedule 14D-9 filing consists of the following communication related to the proposed acquisition of LAVA Therapeutics N.V., a public limited liability company (naamloze vennootschap) organized under the laws of The Netherlands (the “Company”), pursuant to the terms of a Share Purchase Agreement, dated as of August 3, 2025, by and among the Company and XOMA Royalty Corporation, a Nevada corporation:

· Press Release of XOMA Realty Corporation and LAVA Therapeutics N.V. dated August 4, 2025 (Exhibit 99.1)

I-1